Related Experiment Videos
Hemoglobin-based oxygen carriers do not alter platelet functions: study of three chemically modified hemoglobin
Marie Toussaint1, Véronique Latger-Cannard, Alexis Caron
1Université Henri Poincaré Nancy 1, France. marie.toussaint@pharma.uhp-nancy.fr
Intensive Care Medicine
|January 16, 2003
Summary
Three novel hemoglobin-based oxygen carriers (HBOCs) were evaluated for their impact on platelet function. The study found that these HBOCs, similar to hydroxyethylstarch, do not affect platelet activation or aggregation in vitro.
Area of Science:
- Hematology
- Biochemistry
- Biomaterials Science
Background:
- Hemoglobin-based oxygen carriers (HBOCs) are developed as blood substitutes.
- HBOCs may possess vasoactive properties due to nitric oxide scavenging.
- Nitric oxide influences platelet activity.
Purpose of the Study:
- To evaluate the in vitro effects of three structurally distinct HBOCs on platelet function.
- To compare the effects of HBOCs with those of plasma substitutes like hydroxyethylstarch.
Main Methods:
- Platelet activation assessed via flow cytometry measuring glycoproteins (GPIb, GPIIb/IIIa, P-selectin).
- Platelet aggregation evaluated using impedance aggregometry.
- Experiments conducted on platelet-rich plasma and whole blood hemodiluted with HBOCs or hydroxyethylstarch.
Main Results:
- No tested HBOCs induced platelet activation or altered platelet reactivity.
- Surface expression of key glycoproteins remained unchanged.
- No spontaneous platelet aggregation or altered aggregation response to agonists (collagen, TRAP) was observed.
Conclusions:
- Structurally diverse HBOCs did not impact platelet function in vitro.
- The findings suggest HBOCs do not interfere with normal platelet physiology.
- This supports the potential safety of HBOCs regarding hemostasis.